Clinical trials: High Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia

CNDO-109-AANK for AML in First Complete Remission (CR1)

• Unknown status
• Age: 18 years and older
• Phase 1/2
• Results posted

This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…

Trial name

NCT01520558

Testing

CNDO-109-AANK Cells

Where

4 sites in United States

Volunteers

12 people

Sponsor

Coronado Biosciences, Inc.